Metabolic Control of Aging and Disease - the MetAGE Deep Phenotyping Cohort

Korábbi kezelés

• drug abuse, alcohol > 15 drinks/week
• Metal implants that prohibit 3T MRI
• drug abuse, alcohol > 15 drinks/week
• Metal implants that prohibit 3T MRI
• drug abuse, alcohol > 15 drinks/week
• Metal implants that prohibit 3T MRI
• No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
• drug abuse, alcohol > 15 drinks/week
• Metal implants that prohibit 3T MRI
• No previous heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions up until the age of 35 years.
• Metal implants that prohibit 3T MRI

Más betegség

• Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])
• Clinically significant metabolic or endocrine disorders
• Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
• Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])
• Clinically significant metabolic or endocrine disorders
• Heart failure, cardiovascular disease, immunosuppressive therapies, chronic inflammatory diseases and active oncologic conditions
• Highly physical active (i.e. > 5 times sporting activity / week with moderate to high intensity [heart rate 140 - 200bpm])
• Diabetes, overt hypo/hyperthyroidism
• Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
  • Group 4 - Overweight, older adults (n = 150)
• Diabetes, overt hypo/hyperthyroidism
• Clinically significant cognitive impairment compromising study adherence
• Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.

Laborértékek

• Known severe cardiovascular diseases (i.e. PAD IIa or higher, advanced heart failure = left ventricular ejection fraction (LVEF) < 35% or NYHA Class III-IV)

Életkor

• Life-threatening conditions with a life expectancy of less than 1 year or any other condition that would jeopardize proband safety/adherence while participating in this trial.
  • Group 5 - "healthy" Nonagenerians Age ≥ 90 (n = 50)

Egyéb

• Group 1 - Lean, young adults (n = 150)
• Special diets (i.e. ketogenic diet and time-restricted eating)
• Claustrophobia
• Pregnancy or breastfeeding
  • Group 2 - Overweight, young adults (n = 150)
• Special diets (i.e. ketogenic diet and time-restricted eating)
• Active anti-obesity treatment (e.g. glucagon-like peptide 1 (GLP-1) analogues, polyagonists, naltrexone and bupropion)
• Claustrophobia
• Pregnancy or breastfeeding
  • Group 3 - Lean, older adults (n = 150)
• Special diets (i.e. ketogenic diet and time-restricted eating)
• Claustrophobia
• Special diets (i.e. ketogenic diet and time-restricted eating)
• Active anti-obesity treatment (e.g. GLP-1 analogues, polyagonists, naltrexone and bupropion)
• Claustrophobia
• Claustrophobia

• Group 1 - Lean, young adults (n = 150)
• Age 18 - 35 years
• Body mass index (BMI) ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 12 months)
  • Group 2 - Overweight, young adults (n = 150)
• Age 18 - 35 years
• BMI ≥ 28kg/m2 (≥ 12 months)
  • Group 3 - Lean, older adults (n = 150)
• Age ≥ 60 years
• BMI ≥ 18.5 and ≤ 24.9 kg/m2 (≥ 3 years)
  • Group 4 - Overweight, older adults (n = 150)
• Age ≥ 60 years
• BMI ≥ 28 kg/m2 (≥ 3 years)
• Subgroup A (n=75): with pre-existent cardiovascular disease defined as: history of myocardial infarction or evidence of coronary artery disease irrespective of revascularization status or history of ischemic or hemorrhagic stroke or presence of peripheral artery disease or heart failure with preserved ejection fraction (NYHA Class I-II).
• Subgroup B (n=75): without pre-existent cardiovascular disease
  • Group 5 - Nonagenerians Age ≥ 90 (n = 50)
• Age ≥ 90 years
• BMI ≥ 18.5 kg/m2 (≥ 3 years)